Hutox 100 IU 1 vial

Patients should avoid alcohol for at least 24 hours before and after the procedure. Alcohol is a vasodilator that can increase blood flow to the injection sites, potentially worsening post-procedural edema and increasing the risk of bruising at the entry points.

Not recommended. It is unknown if botulinum toxin is excreted in human milk. To maintain maximum safety for the infant, it is advised to postpone treatment until the breastfeeding period has completely concluded.

The formulation contains 100 units of Clostridium botulinum toxin type A, with Human Serum Albumin (0.5mg) and Sodium Chloride (0.9mg) as stabilizers.

Dosage is highly individualized based on the target area and muscle mass. For glabellar lines, the standard protocol is 20 units divided into five injection sites. Practitioners should evaluate if targeted micro-dosing is appropriate for subtle smoothing in delicate zones. The 100 IU vial must be reconstituted with sterile, preservative-free 0.9% sodium chloride before use. A full therapeutic effect is typically observed within 3 to 7 days post-injection.

Common reactions include temporary injection site pain, localized swelling, and purple bruising. Some patients may experience a mild headache or flu-like symptoms during the first 24 hours. To ensure a quick recovery, patients should follow our expert aftercare guide (adapted for toxins) and utilize swelling reduction techniques. Any drooping of the eyelid (ptosis) should be reported to the clinician immediately.

Hutox acts as a neuro-muscular blocking agent. It inhibits the release of acetylcholine from peripheral nerve endings, effectively preventing muscle contraction in the treated area. Unlike skin boosters that hydrate the dermis, Hutox addresses the underlying muscular cause of dynamic wrinkles. This relaxation allows the skin to smooth out, complementing techniques like the Russian lips filler technique by reducing perioral muscle tension.

Strictly contraindicated. No clinical safety data exists for botulinum toxin use during pregnancy. We defer all elective neurotoxin treatments until after childbirth to ensure the highest clinical safety standards are met.